Table 2.
Correlation between RRM2 protein expression and other clinicopathological variables
| Total | RRM2 score | x2 (p value) |
||||
|---|---|---|---|---|---|---|
| Negative | Mild | Moderate | Intense | |||
| Age/ years |
χ2 = 4.07 P = 0.254 |
|||||
| < 60 y | 109 | 21 (19.3%) | 7 (6.4%) | 44 (40.4%) | 37 (33.9%) | |
| ≥ 60 y | 91 | 24 (26.4%) | 3 (3.3%) | 42 (46.2%) | 22 (24.2%) | |
| ER |
χ2 = 4.7 P = 0.196 |
|||||
| Positive | 138 | 36 (26.1%) | 8 (5.8%) | 54 (39.1%) | 40 (29%) | |
| Negative | 62 | 9 (14.5%) | 2 (3.2%) | 32 (51.6%) | 19 (30.6%) | |
| PR |
χ2 = 4.39 P = 0.22 |
|||||
| Positive | 124 | 31 (25.0%) | 8 (6.5%) | 47 (37.9%) | 38 (30.6%) | |
| Negative | 76 | 14 (18.4%) | 2 (2.6%) | 39 (51.3%) | 21 (27.6%) | |
| HER2/neu |
χ2 = 3.75 P = 0.312 |
|||||
| Positive | 45 | 7 (15.6%) | 2 (4.4%) | 18 (40.0%) | 18 (40.0%) | |
| Negative | 155 | 38 (24.2%) | 8 (5.2%) | 68 (43.9%) | 41 (26.5%) | |
| Ki67 median expression | 200 | 5 (2–40) | 5 (5–40) | 5 (5–50) | 10 (2–60) |
KW = 9.18 P = 0.027* |
| Type |
MC P = 0.736 |
|||||
| Luminal A | 75 | 21 (28.0%) | 3 (4.0%) | 29 (38.7%) | 22 (29.3%) | |
| Luminal B | 40 | 9 (22.5%) | 3 (7.5%) | 16 (40.0%) | 12 (30.0%) | |
| TN BLBC | 39 | 9 (23.1%) | 2 (5.1%) | 16 (41.0%) | 12 (30.8%) | |
| Her2 Luminal | 17 | 2 (11.8%) | 2 (11.8%) | 8 (47.1%) | 5 (29.4%) | |
| Her2 enriched | 29 | 4 (13.8%) | 0 (0%) | 17 (58.6%) | 8 (27.6%) | |
| EGFR |
χ2 = 4.62 P = 0.202 |
|||||
| Positive | 150 | 39 (26.0%) | 8 (5.3%) | 61 (40.7%) | 42 (28.0%) | |
| Negative | 50 | 6 (12.0%) | 2 (4.0%) | 25 (50.0%) | 17 (34.0%) | |
| Histological type |
MC P = 0.326 |
|||||
| Ductal | 173 | 39 (22.5%) | 9 (5.2%) | 76 (43.9%) | 49 (28.3%) | |
| TIL-rich IBC-NST | 4 | 0 (0%) | 1 (25.0%) | 2 (50.0%) | 1 (25.0%) | |
| Mucinous | 5 | 3 (60.0%) | 0 (0%) | 1 (20.0%) | 1 (20.0%) | |
| Lobular | 15 | 2 (13.3%) | 0 (0%) | 7 (46.7%) | 6 (40.0%) | |
| Micropapillary | 3 | 1 (33.3%) | 0 (0%) | 0 (0%) | 2 (66.7%) | |
| Grade (n = 173) |
χ2 = 0.757 P = 0.847 |
|||||
| I & II | 139 | 33 (23.7%) | 10 (7.2%) | 46 (33.1%) | 50 (36.0%) | |
| III | 34 | 7 (20.6%) | 1 (2.9%) | 17 (50.0%) | 9 (26.5%) | |
| Multicent |
MC P = 0.629 |
|||||
| Positive | 6 | 1 (16.7%) | 1 (16.7%) | 2 (33.3%) | 2 (33.3%) | |
| Negative | 194 | 44 (22.7%) | 9 (4.6%) | 84 (43.3%) | 57 (29.4%) | |
| Tumour size |
χ2 = 0.685 P = 0.877 |
|||||
| T1& 2 | 147 | 34 (23.1%) | 7 (4.8%) | 61 (41.5%) | 45 (30.6%) | |
| T3 & 4 | 53 | 11 (20.8%) | 3 (5.7%) | 25 (47.2%) | 14 (26.4%) | |
| Lymph node |
χ2 = 4.53 P = 0.209 |
|||||
| No & N1 | 107 | 21 (19.6%) | 8 (7.5%) | 49 (45.8%) | 29 (27.1%) | |
| N2 & N3 | 93 | 24 (25.8%) | 2 (2.2%) | 37 (39.8%) | 30 (32.3%) | |
| Tumour stage |
χ2 = 4.89 P = 0.180 |
|||||
| I & II | 94 | 21 (22.3%) | 8 (8.5%) | 40 (42.6%) | 25 (26.6%) | |
| III | 106 | 24 (22.6%) | 2 (1.9%) | 46 (43.4%) | 34 (32.1%) | |
| Recurrence |
χ2 = 29.7 P ≤ 0.001* |
|||||
| Yes | 61 | 9 (14.8%) | 3 (4.9%) | 15 (24.6%) | 34 (55.7%) | |
| No | 139 | 36 (25.9%) | 7 (5.0%) | 71 (51.1%) | 25 (18.0%) | |
χ2: Chi square test, KW Kruskil Wallis test, MC Monte Carlo test, *significant p ≤ 0.05